Anti-VEGF the mainstay in DME management

As a second-line agent, steroids may be used in combination anti-VEGF

Anti-VEGF the mainstay in DME management
Dermot McGrath
Dermot McGrath
Published: Monday, September 9, 2019
Although anti-vascular endothelial growth factor (anti-VEGF) drugs remain first-line agents in the management of diabetic macular oedema (DME), corticosteroids may still play a role in patients where anti-VEGF is contraindicated, unavailable or unaffordable, according to Sobha Sivaprasad MD. “We know that the visual outcome will not be as good as anti-VEGF when using steroids. As a second-line agent, steroids may potentially be used in combination with an anti-VEGF agent. Although it has been recommended in pseudophakics who are non-responsive to anti-VEGF, the recent evidence from the Protocol U study suggests that very few patients will actually benefit,” she said. In DME cases where there is no visual impairment, the best strategy is observation, said Dr Sivaprasad. She advised that any of the approved anti-VEGF agents should be administered on a tight treatment schedule in cases of DME with mild visual impairment. For patients whose visual acuity of 20/50 or worse, aflibercept should be the agent of choice as it performs better in more severe cases, she said. For proliferative diabetic retinopathy (PDR), panretinal photocoagulation remains the standard of care in 2019. “Anti-VEGF treatments may offer significant advantages but we need a good surveillance programme to be able to provide urgent anti-VEGF therapy if there is recurrence or reactivation of new vessels as non-perfusion continues to increase. The complications are disastrous if not treated properly in these cases,” she concluded.
Tags: anti-VEGF, corticosteroid use, diabetic macular oedema (DME)
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...